Department of Endocrine and Oncology Surgery, Royal North Shore Hospital, Sydney, Australia.
Thyroid. 2012 Feb;22(2):205-9. doi: 10.1089/thy.2011.0276. Epub 2012 Jan 6.
Primary mucoepidermoid carcinoma (MEC) of the thyroid is a rare clinical and pathological entity that accounts for <0.5% of all thyroid malignancies. Although the histogenesis has been controversial, most investigators now favor it as arising from either metaplasia of thyroid follicular epithelium or heterologous de-differentiation from papillary thyroid carcinoma (PTC). We report three cases of thyroid MEC found in continuity with, and clearly arising from de-differentiation of, well-differentiated thyroid carcinomas (WDTCs).
The cases presented here included two women (aged 22 and 52) and one man (aged 58). One of these cases arose in conjunction with PTC, one with follicular thyroid carcinoma (FTC), and one with Hurthle cell carcinoma (HCC). In all three cases, there was a gradual transition in morphology between the areas of typical WDTC and the areas showing MEC differentiation. In addition, immunohistochemistry demonstrated a gradual loss of thyroid specific markers (thyroid transcription factor-1, thyroglobulin) mirroring the change in morphology.
We conclude that thyroid MEC can arise from metaplastic de-differentiation of WDTC, including FTC or HCC in addition to PTC. Currently, we recommend that after excision, each of the WDTC and MEC components of these tumors be treated with targeted adjuvant therapies, which may involve radioactive-iodine ablation, thyrotropin suppression, and external beam radiotherapy.
甲状腺原发性黏液表皮样癌(MEC)是一种罕见的临床和病理实体,占所有甲状腺恶性肿瘤的<0.5%。尽管其组织发生一直存在争议,但大多数研究人员现在认为它是由甲状腺滤泡上皮的化生或源自甲状腺乳头状癌(PTC)的异源去分化而来。我们报告了三例与分化良好的甲状腺癌(WDTC)连续性存在并明显起源于去分化的甲状腺 MEC。
此处介绍的三个病例包括两名女性(年龄分别为 22 岁和 52 岁)和一名男性(年龄为 58 岁)。其中一个病例与 PTC 一起发生,一个与滤泡状甲状腺癌(FTC)一起发生,一个与 Hurthle 细胞癌(HCC)一起发生。在所有三个病例中,在典型 WDTC 区域与显示 MEC 分化的区域之间存在形态学的逐渐转变。此外,免疫组织化学显示甲状腺特异性标志物(甲状腺转录因子-1、甲状腺球蛋白)逐渐丢失,与形态变化相吻合。
我们得出结论,甲状腺 MEC 可能起源于 WDTC 的化生去分化,包括 PTC 以外的 FTC 或 HCC。目前,我们建议在切除后,这些肿瘤的每个 WDTC 和 MEC 成分都应采用靶向辅助治疗,其中可能包括放射性碘消融、促甲状腺激素抑制和外照射放疗。